Transcept Pharmaceuticals, Inc. (TSPT)
-NasdaqGM | Prev Close: | 3.16 |
|---|
| Open: | N/A |
|---|
| Bid: | 3.00 x 100 |
|---|
| Ask: | 3.16 x 4400 |
|---|
| 1y Target Est: | 4.31 |
|---|
| Beta: | 0.59 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 3.05 - 7.45 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 137,210 |
|---|
| Market Cap: | 59.27M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.95 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- TRANSCEPT PHARMACEUTICALS INC FinancialsEDGAR Online Financials(Fri, May 17)
- Locust Walk Partners Announces Appointment of Chris Ehrlich, Biotechnology Industry and Venture Capital Veteran, as Managing DirectorMarketwired(Tue, May 14)
- TRANSCEPT PHARMACEUTICALS INC Files SEC form 8-K, Other EventsEDGAR Online(Mon, May 13)
- Transcept Pharmaceuticals downgraded to Hold from Buy at MLV Equitytheflyonthewall.com(Fri, May 10)
- Transcept Pharma downgraded by MLV & CoBriefing.com(Fri, May 10)
- Transcept: Throwing In The Towel On Intermezzoat Seeking Alpha(Thu, May 9)
- TRANSCEPT PHARMACEUTICALS INC Files SEC form 8-K/A, Costs Associated with Exit or Disposal ActivitiesEDGAR Online(Thu, May 9)
- Transcept downgraded to Market Perform from Outperform at JMP Securitiestheflyonthewall.com(Thu, May 9)
- Transcept downgraded to Market Perform from Outperform at Leerinktheflyonthewall.com(Thu, May 9)
- Transcept Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Wed, May 8)
- Transcept Pharmaceuticals Reports First Quarter 2013 Financial ResultsPR Newswire(Wed, May 8)
- Narrower-than-Expected Loss at Seattle GeneticsZacks(Wed, May 8)
- TRANSCEPT PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsEDGAR Online(Wed, May 8)
- Impax Beats Earnings EstimateZacks(Thu, May 2)
- Transcept Pharmaceuticals to Report First Quarter 2013 Financial Results and Host Conference Call on May 8, 2013PR Newswire(Wed, May 1)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 17.60 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.24 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.34 |
|---|
| Mean Recommendation*: | 2.5 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Transcept Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of proprietary products that address therapeutic needs in the field of neuroscience.
View More 
0.12%